CTI BioPharma has reported topline data where its oral drug, pacritinib, failed to meet statistical significance for the primary goal of the PRE-VENT clinical trial in severe Covid-19 patients admitted to hospital.
Pacritinib is an experimental oral kinase inhibitor.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The double-blind, randomised, placebo-controlled multicentre trial analysed pacritinib plus standard of care against placebo plus standard of care in Covid-19 subjects and included those with and without cancer.
The proportion of subjects advancing to receive invasive mechanical ventilation and/or extracorporeal membrane oxygenation or succumbed by day 28 was the trial’s primary goal.
The trial was recently modified to a Phase II design due to the accessibility to Covid-19 vaccines and the evolving pandemic situation.
The final assessment was carried out after randomising 200 subjects in the trial.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataAccording to the trial findings, 26.3% of subjects in the pacritinib arm progressed to receive invasive mechanical ventilation and/or extracorporeal membrane oxygenation or died by day 28 Versus 24.8% in the placebo arm.
Data suggest that the treatment did not offer a statistically significant improvement in the primary goal, CTI BioPharma noted.
Pacritinib was demonstrated to be well-tolerated in subjects with reduced rates of grade 3+ events.
Serious adverse events were observed in the pacritinib arm versus the placebo arm.
CTI BioPharma president and CEO Adam Craig said: “Last year, we launched the PRE-VENT study of pacritinib in patients with severe Covid-19 in response to the pandemic and an unprecedented medical need to improve outcomes for these patients.
“Although pacritinib was well tolerated on study, it did not demonstrate a clinical benefit in treating the sickest patients with Covid-19.”
Based on the latest trial data, the company decided not to progress the pacritinib development to treat patients with severe Covid-19.
